Issue link: https://www.e-digitaleditions.com/i/1546950
Inhalation OctOber 2026 19 Designing inhalation devices for next-generation propellants e transition to low-GWP propellants is introducing new considerations in the development of pressurized metered dose inhalers (pMDIs). Changes in propel- lant properties, including density, vapor pressure and boiling point, can influence formulation behavior, aerosolization and spray characteristics. ese factors may also affect key performance measures such as Aerodynamic Particle Size Distribution (APSD) and Delivered Dose Uniformity (DDU). As device and formulation development evolve, testing approaches need to account for these changes. Understanding the interaction between propellant, formulation, device and testing conditions is an important part of eval- uating next-generation inhalers and supporting con- sistent performance throughout development. Learn more: https://tsi.news/4d0kkwp. MSP™, a Division of TSI ® US: +1 651 287-8100 mspsales@tsi.com www.tsi.com An advanced aerosol generator PreciseInhale ® is the advanced aerosol generator sometimes known as "e Inhalation Switchboard" because it can consistently generate aerosol from sev- eral sources (DPIs, MDIs, nebulizers, dry powders), enabling precision dosing across a wide range of advanced in vitro and in vivo exposure modules, min- imizing translational errors and generating compar- ative and more predictive data. e extensive range of high-precision exposure modules minimizes errors, reduces risk and accelerates drug development. Inhalation Sciences AB Sweden: +46 705 625 195 contact@inhalation.se www.inhalation.se Particle characterization instruments Every breakthrough in inhalation begins with under- standing the particles that deliver it. Across formu- lation development, device optimization, quality control and regulatory science, accurate characteri- zation helps transform observations into knowledge. Drawing on decades of experience and an expanded Malvern Panalytical portfolio including key analyt- ical techniques for assessing particle size and shape, and aerated and flow energy as well as polymorphism and crystallinity, we are proud to support the inha- lation community through scientific collaboration, education and innovation. Together with research- ers, industry partners and regulatory stakeholders, we remain focused on advancing the measurement sci- ence that helps bring inhaled therapies to patients. Malvern Panalytical US: +1 978 872-4870 maria.lightfoot@malvernpanalytical.com www.malvernpanalytical.com

